Features - VJNeurology

ENRICH trial demonstrates efficacy of minimally invasive surgery in intracerebral hemorrhage

ENRICH is a two-arm, multicenter, randomized, adaptive clinical trial assessing the effectiveness of minimally invasive trans-sulcal parafascicular surgery (MIPS) for…

Gepants: updates on current use and future directions for migraine treatment

Recent years have seen a revolution in the development and use of gepants as acute and preventive treatments for migraine….

Trofinetide approved by FDA as first ever treatment for Rett syndrome

On March 10th 2023, the Food and Drug Administration (FDA) approved trofinetide in the treatment of Rett syndrome (RTT), making…

First ever targeted treatment for SOD1-ALS: FDA approve tofersen

On April 25th, 2023, the U.S. Food and Drug Administration (FDA) approved tofersen (BIIB067) for the treatment of amyotrophic lateral…

Newborn screening improves health outcomes in infants with spinal muscular atrophy

Spinal muscular atrophy (SMA) is a severe genetic disease associated with mutations in the SMN1 gene (SMA5q). The pathological characteristics…

Relaunching the GENERATION HD trial: how will tominersen fare with younger, milder Huntington’s disease patients?

Following the termination of the GENERATION HD1 trial in March 2021, Roche have now announced plans for a new Phase…

FDA approves ublituximab for relapsing multiple sclerosis

The Food and Drug Administration (FDA) approved ublituximab for the treatment of relapsing forms of multiple sclerosis (MS), making it…

Active seizures worsen clinical and mortality outcomes for patients with dementia

New data presented at the American Epilepsy Society (AES) 2022 annual meeting has demonstrated that the presence of active seizures…